Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Operating Leases (2021 - 2025)

Anaptysbio filings provide 5 years of Operating Leases readings, the most recent being $12.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 14.74% year-over-year to $12.0 million, compared with a TTM value of $12.0 million through Dec 2025, down 14.74%, and an annual FY2025 reading of $12.0 million, down 14.74% over the prior year.
  • Operating Leases hit $12.0 million in Q4 2025 for Anaptysbio, down from $14.6 million in the prior quarter.
  • The five-year high for Operating Leases was $20.9 million in Q3 2021, with the low at $12.0 million in Q4 2025.
  • Median Operating Leases over the past 5 years was $16.5 million (2024), compared with a mean of $17.1 million.
  • The largest YoY upside for Operating Leases was 0.01% in 2024 against a maximum downside of 18.28% in 2024.
  • Year by year, Operating Leases stood at $19.4 million in 2021, then fell by 8.42% to $17.8 million in 2022, then dropped by 9.97% to $16.0 million in 2023, then dropped by 12.0% to $14.1 million in 2024, then decreased by 14.74% to $12.0 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $12.0 million, $14.6 million, and $15.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.